Strategic partnerships ClearPoint Neuro has active and recent collaboration momentum including a 10-year focused ultrasound development partnership with Sungkyunkwan University and ongoing international engagement, signaling a strong appetite for research-driven, joint development opportunities that can expand market access and co-develop new navigation-enabled therapies.

Regulatory expansion With EU MDR certifications achieved for ClearPoint Navigation Software Version 3.0.2 and continued European access, there is a clear pathway to scale sales in Europe, suggesting targeting EU hospitals, clinics, and research centers deploying/mursing brain and spine navigation solutions.

Revenue growth First-quarter 2026 revenue of 12.1 million, up 43% year over year driven by IRRAflow and device demand, indicates accelerating demand for navigation-enabled neurological therapies and related service lines, presenting upsell opportunities to existing customers and expansion into adjacent neurosurgical centers.

Leadership expansion Appointment of a new Chief Medical Officer in 2026 signals a strategic emphasis on clinical leadership and peer-to-peer outreach, creating a conducive environment for clinical adoption programs, physician education, and expanded case volumes through hospital networks.

Global expansion Active engagement across North America, Europe, Asia, and South America, plus a recent acquisition activity, positions ClearPoint to pursue multi-region deployments, channel partnerships, and cross-border sales to large neurosurgical and research institutions seeking precise brain and spine navigation capabilities.